Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells

Leukemia

Volumn 28, Issue 5, 2014, Pages 1158-1163

  Zhong, Y ^a   El Gamal, D ^a   Dubovsky, J A ^a   Beckwith, K A ^a   Harrington, B K ^b   Williams, K E ^a   Goettl, V M ^a   Jha, S ^a   Mo, X ^a   Jones, J A ^a   Flynn, J M ^a   Maddocks, K J ^a   Andritsos, L A ^a   McCauley, D ^c   Shacham, S ^c   Kauffman, M ^c   Byrd, J C ^a   Lapalombella, R ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c Karyopharm Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; EXPORTIN 1; FOSTAMATINIB; IBRUTINIB; IDELALISIB; IMMUNOGLOBULIN HEAVY CHAIN; MITOGEN ACTIVATED PROTEIN KINASE; PRE B CELL RECEPTOR; PROTEIN KINASE SYK; SELINEXOR; TOLL LIKE RECEPTOR 9;

ANIMAL EXPERIMENT; ANIMAL MODEL; B LYMPHOCYTE ACTIVATION; CELL EXPANSION; CELL ISOLATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DOWNSTREAM PROCESSING; DRUG EFFICACY; DRUG INHIBITION; ENZYME PHOSPHORYLATION; IMMUNOBLOTTING; LETTER; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN CROSS LINKING;

B-LYMPHOCYTES; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; HYDRAZINES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE ACTIVATION; TRIAZOLES;

EID: 84899920472     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.9     Document Type: Letter

References (15)

1. Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, Vire B. et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011; 117: 563-574.
2. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-1854.
3. Longo PG, Laurenti L, Gobessi S, Petlickovski A, Pelosi M, Chiusolo P. et al. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia 2007; 21: 110-120.
4. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A. et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010; 115: 2578-2585.
5. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32-42.
6. Hoellenriegel J, Coffey GP, Sinha U, Pandey A, Sivina M, Ferrajoli A. et al. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia 2012; 26: 1576-1583.
7. Herman SE, Barr PM, McAuley EM, Liu D, Wiestner A, Friedberg JW. Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia. Leukemia 2013; 27: 1769-1773.
8. Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, Zhong Y. et al. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood 2012; 120: 4621-4634.
9. Haferlach C, Mecucci C, Schnittger S, Kohlmann A, Mancini M, Cuneo A. et al. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. Blood 2009; 114: 3024-3032.
10. Lam DH, Aplan PD. NUP98 gene fusions in hematologic malignancies. Leukemia 2001; 15: 1689-1695.
11. Tabe Y, Kojima K, Jin L, Iwanami H, Matsushita H, Kazuno S. et al. Molecular mechanisms of inhibition of ribosomal biogenesis and translational flux by the selective inhibitor of nuclear export (SINE) XPO1/CRM1 antagonist KPT-185 in mantle cell lymphoma. Blood 2013; 122: 820.
12. Tagoug I, Neri P, Slaby J, Babich J, Simms J, Gratton K. et al. XPO1 inhibition disrupts ribosomal subunits assembly and induces multiple myeloma (MM) cell death. Blood 2013; 122: 3165.
13. Kuruvilla J, Gutierrez M, Shah BD, Gabrail NY, de Nully Brown P, Stone RM. et al. Preliminary evidence of anti tumor activity of selinexor (KPT-330) in a phase I trial of a first-in-class oral selective inhibitor of nuclear export (SINE) in patients (pts) with relapsed/refractory non Hodgkin?s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Blood 2013; 122: 90.
14. Yu L, Mohamed AJ, Simonson OE, Vargas L, Blomberg KE, Bjorkstrand B. et al. Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF-kappaB. Blood 2008; 111: 4617-4626.
15. Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 1999; 94: 3658-3667.